Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Wednesday 18 October, 2000

Xenova Group PLC

Research Update

Xenova Group PLC
18 October 2000

           Xenova Group plc: XR9576 Phase II Cancer Programme Update
                   Further positive Phase IIa trial results

Slough, UK, 18 October 2000

Xenova Group plc (Nasdaq: XNVA) (London Stock Exchange: XEN) today announced a
programme update for its Phase II clinical trial candidate, XR9576.

A positive outcome has been confirmed in the second of three Phase IIa PK
(pharmacokinetic) trials, in which XR9576 was administered in combination
therapy with doxorubicin, one of the world's most frequently used cytotoxic
drugs. XR9576 is a P-glycoprotein pump (P-gp) inhibitor, designed to address
the problems of multi-drug resistance in cancer.  It is estimated that,
depending on the type of cancer, between 30% and 80% of cancer patients
develop resistance to anti-cancer drugs.  The most common form of this
resistance is the over-production of a membrane protein, known as P-gp, which
pumps anti-cancer drugs out of cells.

This XR9576/doxorubicin study is the second to be completed in a series of
three trials designed to assess the level of drug:drug interaction, if any,
between XR9576 and the cytotoxic in question. The positive results of a Phase
IIa PK study, in which XR9576 was administered with paclitaxel, the world's
leading selling cancer drug, and which was carried out in relapsed ovarian
cancer patients, were reported in March 2000.  In the paclitaxel study, XR9576
showed no clinically significant PK interaction, allowing paclitaxel to be
administered at its full clinical dose.

Commenting on the doxorubicin study, principal investigator Dr David Ferry, of
the Queen Elizabeth Medical Centre, Birmingham, UK said: 'We are very pleased
with the outcome of this study.  P-gp has been a difficult area to work in,
with variable and in some cases significant interactions observed between many
of the previously investigated P-gp inhibitors and the co-administered
cytotoxics.  However, this trial has shown XR9576 to have only minor and
predictable effects when used with doxorubicin. XR9576's lack of variable and
clinically significant PK interaction should provide an advantage in clinical
practice, in that it could allow many different cytotoxic drugs to be used at
or close to their normal doses.'

Dr Hilary Thomas, Professor of Oncology at the Royal Surrey Hospital,
Guilford, UK and principal investigator for the paclitaxel/ovarian trial,
commented saying: 'Ideally, multi-drug resistance modulators should allow
cytotoxic drugs to be administered at or as close as possible to their normal
dosing levels. In the study, which we completed earlier this year in relapsed
ovarian patients, XR9576 showed no sign of toxicity associated with XR9576
itself and no sign of clinically significant effects on paclitaxel levels.
This allowed us to use paclitaxel at its full normal dosing levels, a
potentially important and differentiating capability.'

A third Phase IIa study, in which XR9576 is being administered in combination
with vinorelbine, another leading cancer drug, is scheduled for completion
shortly. This study is being carried out at the National Cancer Institute in
the USA.

As previously reported, it is expected that XR9576 will be ready to enter
pivotal Phase III clinical trials by the end of 2000.  The positive outcome of
the doxorubicin PK study, as announced today, provides additional clinical
options for the design of these Phase III studies.

Commenting, David Oxlade, Chief Executive Officer of Xenova Group plc, said:
'Multi-drug resistance remains one of the major barriers to treatment in many
forms of cancer.  We are delighted with the continued progress shown by


Xenova Group plc
Tel: +44 (0)1753 706600
David A Oxlade, Chief Executive Officer
Daniel Abrams, Finance Director
Hilary Reid Evans, Corporate Communications

Noonan/Russo Communications Inc
Tel: 001 212 696 4455
Tony Ho Loke (Media)

Financial Dynamics
Tel: +44 (0)20 7831 3113
Sophie Pender-Cudlip

Xenova Group plc is a London Stock Exchange techMARK listed company.

Notes to Editors

Xenova Group plc is an emerging bio-pharmaceutical company specialising in the
development of new small molecule drugs.  The company's strategy is to develop
commercially attractive new drugs, primarily in the area of cancer

 In addition to its two Phase II programme drugs (XR9576 and topoisomerase I
and II inhibitor XR5000) Xenova is also currently undertaking cancer research
projects targeting MRP-related multi-drug resistance, further next generation
topoisomerase inhibitors, telomerase (with Brunel University) and plasminogen
activator inhibitor-1 (PAI-1).  Xenova has a drug development agreement with
Lilly, based on small molecule inhibitors of PAI-1, to develop novel
antithrombotic drugs for chronic use.

For further information about Xenova and its products please visit the Xenova
website at

Safe Harbor Statement under the US Private Securities Litigation Reform Act of
1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995.  Actual results of events could differ materially from those described
in the forward-looking statements due to a variety of factors, including those
set forth in the Company's filings with the US Securities and Exchange


a d v e r t i s e m e n t